Novel ALK2 inhibitory compound may be a candidate FOP treatment
Swiss researchers have identified a novel compound that selectively inhibits activin receptor-like kinase 2 (ALK2) and may be a future candidate for the treatment of fibrodysplasia ossificans progressive (FOP).